Jan 27, 2021 / 10:30AM GMT
Cyndrella Carvalho - Centrum Broking Pvt. Ltd - Moderator
(audio in progress) hand-over the call to Mr. Adhish. Over to you for the opening remarks.
Adhish Patil - Aarti Drugs Ltd - CFO
Thank you, Cyndrella. Good evening, everyone. Welcome all of you on behalf of the entire management of Aarti Drugs Limited for the earnings call for the December 2020 quarter. In the December 2020 quarter, the company recorded consolidated quarterly revenue from operations of INR530.25 crores, with year-on-year increase of 11.98%. API segment contributed approximately 87% and formulation segment around 13% of the total consolidated revenues.
Within the API segment, 66.89% of the revenues came from domestic market and 33.11% from the export market. In the formulation division, 31.01% of the sales came from exports in this quarter. Domestic sales of the API segment grew by approximately 13.5% and exports by around 13.77%. Around 66% of this growth in the API segment was driven by volume growth due to good demand across multiple therapies.
Formulations segment
Q3 2021 Aarti Drugs Ltd Earnings Call Transcript
Mar 20, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers